Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 8:00 AM ESTÂ Net product revenue of $42.1M in 4Q and $50.7M for the year
  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation
  Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients
  First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024
  Strong balance sheet, closing the year with $594.1M in cash and investments
